comparemela.com

Latest Breaking News On - Cabotegravir - Page 1 : comparemela.com

Clinical Challenges: How to Combat PrEP-Associated Stigma

Despite evolving care and medication options, it's still an uphill battle

New yorkUnited statesAntonio urbinaMonica gandhiUs preventive services task forceWorld health organizationUniversity of california san franciscoIcahn school of medicine at mount sinaiSexually transmitted infectionsCalifornia san franciscoMeeting patients where they reIcahn schoolMount sinaiNew york cityServices task forceHiv infection

Uganda to roll out injectable HIV drug

The drug was cleared by the World Health Organisation after studies showed it is safe and effective in preventing HIV infection.

United statesUnited kingdomSouth africaDaniel byamukamaGlobal fundWorld health organisationMedicines control authority of zimbabweUganda aids commissionViiv healthcareAids symposiumKololo independence groundsMedicines control authorityInjectable hiv drugHiv aids preventionUganda aids commissionHiv aids

Is the end of AIDS in sight?

The virus can be brought under control. But it’s complicated

Saudi arabiaKwazulu natalSouth africaEastern capeUnited statesSouth africanPeter sandsMakhosazana molotsaneThabo mbekiGeorgew bushThulina moukangweDeborah waterhouseRonnie sibisiSibongile tshabalalaNokwanda gambusheQuarraisha abdool karim

Cipla, Aurobindo, Viatris in licensing pact with MPP to produce generic versions of ViiV Healthcare HIV drug

Aurobindo and Viatris will manufacture in India; Cipla will manufacture in India and has plans to manufacture in South Africa as well.

South africaPhilippe dunetonMitchell warrenDeborah waterhouseCharles goreDrug administrationGlobal fundWorld health organizationCoalition to accelerate access longSaharan africaViiv healthcareSaharan africanExecutive directorAccelerate accessMedicines patent pool

ViiV Healthcare Announces Positive Data Demonstrating Long-acting Injectable Cabenuva (cabotegravir, rilpivirine) is as Effective as Daily Oral Biktarvy (BIC/FTC/TAF) for the Treatment of HIV-1

12-month findings from the SOLAR study showed that the every-two-month regimen of CAB+RPV LA demonstrated non-inferior efficacy compared to continuation of daily oral BIC/FTC/TAF 90% of participants

United kingdomUnited statesNorth carolinaCity ofUnited kingdom generalDennis riedlDan smithKathleen quinnCamilla campbellJosh williamsJeff mclaughlinMick readeyAudrey abernathyLyndsay meyerTim foleyJames dodwell

vimarsana © 2020. All Rights Reserved.